HRS: Endosense, Siemens partner for heart modeling
Endosense and Siemens Healthcare have partnered and developed prototyping software to integrate into Endosense's TactiCath force-sensing ablation catheter that provides electrophysiologists a 3D model of the heart during ablation.
The joint agreement that began January combines Siemens EP solutions with Endosense’s TactiCath to enhance visualization during the treatment of arrhythmias. According to the company, the new software will enable EPs to measure and control force, in addition to viewing the 3D photo of the heart’s anatomy.
Currently, the TactiCath system is an investigational device. At this year’s Heart Rhythm Society meeting in San Francisco during early May, Endosense released data supporting the TactiCath device. Specifically, the Geneva-based company issued results for its EFFICAS I post-marketing clinical trial that evaluated the use of TactiCath during pulmonary vein isolation (PVI) and atrial fibrillation (AF) procedures.
At three months, results showed an association between low force time integral at first ablation and early gap occurrence following PVI.
Additionally at HRS, Endosense released that use of TactiCath:
The company said that it will be enrolling patients into the EFFICAS II trial that will measure reductions in PVI gaps and improvements compared with EFFICAS I.
The joint agreement that began January combines Siemens EP solutions with Endosense’s TactiCath to enhance visualization during the treatment of arrhythmias. According to the company, the new software will enable EPs to measure and control force, in addition to viewing the 3D photo of the heart’s anatomy.
Currently, the TactiCath system is an investigational device. At this year’s Heart Rhythm Society meeting in San Francisco during early May, Endosense released data supporting the TactiCath device. Specifically, the Geneva-based company issued results for its EFFICAS I post-marketing clinical trial that evaluated the use of TactiCath during pulmonary vein isolation (PVI) and atrial fibrillation (AF) procedures.
At three months, results showed an association between low force time integral at first ablation and early gap occurrence following PVI.
Additionally at HRS, Endosense released that use of TactiCath:
- Was associated with a higher rate of AF recurrence in patients at 12 months (long-term TOCCATA clinical study);
- Contact-force measurement with the device is safe and effective and can reduce radiofrequency time compared to standard irrigated-tip catheters; and
- Contact-force and force-time-integral mapping and visualization techniques may help electrophysiologists identify potential areas of PVI line reconduction that contribute to long-term AF recurrence.
The company said that it will be enrolling patients into the EFFICAS II trial that will measure reductions in PVI gaps and improvements compared with EFFICAS I.